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1.1. A short history of surgery in musculoskeletal 
oncology 
In the 19th century the primary choice of surgical 
treatment in musculoskeletal oncology was amputation. 
This choice was based on the observation that resec- 
tions were frequently followed by local recurrences and 
that the mortality rate after resection was high [l]. 
Before the 1970s treatment of osteogenic sarcoma con- 
sisted of radiotherapy and amputative surgery in many 
cases, according to the protocol, as described by Cade 
[2]. It took surgeons more than half a century to see that 
reconsideration of this conduct was desirable. Surgery 
had improved as well as the skills of anaesthesiologists, 
pathologists and radiologists. It seemed feasible to try to 
preserve a limb or joint in cases [3-51 where limb 
salvage would not cause more risk to life than other 
types of treatment, and in palliative cases such as 
metastatic bone disease. 
Just after World War II, John Scales in the United 
Kingdom started to develop megaprostheses for recon- 
struction of large defects after musculoskeletal surgery 
[5]. In 1958 Merle d’Aubigne [6] described aspecial type 
of resection-arthrodesis, which he used in ‘diaphyseal- 
epiphyseal’ tumors around the knee. Limb saving sur- 
gery was born. Nilsonne [7] had the courage to treat 
patients with a tumor of the pelvis with a less mutilating 
operation compared to hemipelvectomy. He performed 
a resection of the periacetabular region, kept the leg in- 
tact in situ and called this an ‘internal hemipelvectomy’. 
Ottolenghi [8] and Mankin [9] developed a type of re- 
construction in which they made use of homogenous 
bone allografts. This type of treatment was based on the 
observations of Chase and Herndon [lo] who had 
studied the fate of autogenous and homologenous bone 
grafts. 
Because reconstruction with the aid of prostheses or 
allografts was expensive, Pho [l l] ‘started to use 
vascularized autogenous bone grafts for reconstruction 
of defects. However, these types of reconstruction as 
part of limb saving surgery would never have reached 
the modem state of the art without the major steps for- 
ward which took place in radiology [ 121, chemotherapy 
[ 13- 151, radiotherapy [ 16,171 and oncologic staging 
[ 131. Codman’s [ 181 triangle as an indication of rapid 
growth by extracortical spread has been known since 
1926 and Lodwick’s [ 19) classification of radiological 
patterns of bone destruction in geographic, permeative 
and moth-eaten lesions has been used since 1966. Angio- 
graphy was able to detect vascular involvement and soft 
tissue extension, but is nowadays seldom used for this 
purpose. CT scans and MRI are replacing angiography 
for this purpose [20]. 
Skeletal technetium scintigraphy [21] was, and is, ex- 
tremely useful in the detection of primary and metastatic 
bone tumors. However, the uptake of a bone seeking 
isotope is non-specific and non-diagnostic. 
The introduction of computed tomography [22] in 
musculoskeletal oncology in 1979 enhanced the visual- 
isation of the extension of tumor in the medulla and soft 
tissues. This was a major step forward. 
Since 1977 nuclear magnetic resonance [23] has been 
used for imaging purposes. It appears to be extremely 
useful for defining the intramedullary extent, soft tissue 
spread, presence of skip-lesions and response to chemo- 
therapy. Although its value for diagnostic purposes is 
beyond doubt, this technique is still complementary to 
other imaging techniques [24]. 
Diagnostic strategy in bone and soft tissue tumors has 
become extremely important in the treatment of these 
tumors [25]. 
1.2. Improvements in chemotherapy for musculoskeletal 
oncology 
Before the advent of chemotherapy the outcome for 
patients with musculoskeletal malignancies was very 
poor. Combined surgical and radiotherapeutic therapy 
was able to cure only 10% of patients with Ewing’s sar- 
coma [26], 20% of patients with osteosarcoma [27], and 
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14% of children with soft tissue tumors, especially rhab- 
domyosarcoma [28]. Between 1955 and 1970, several 
workers demonstrated objective tumor regression after 
the administration of new chemotherapeutic agents, 
such as actinomycine D [29], cyclophosphamide [30], 
vincristine [31], adriamycine [32-341, and high-dose 
methotrexate [35-371. Single agent therapy with these 
agents was able to induce a percentage of complete and 
partial responses in the order of 20-50%. Adjuvant 
chemotherapy using combinations of these agents began 
after 1970. The most important initial chemotherapeutic 
schemes consisted of a combination of vincristine, ac- 
tinomycine D and cyclophosphamide in patients with 
soft tissue tumors and Ewing’s sarcomas [38], and high- 
dose methotrexate in patients with osteosarcoma [39]. 
After 1970 multi-institutional trials [40,134] recruited 
large numbers of patients with the aim of answering 
therapeutic and prognostic questions within a reason- 
able period of time. Examples of the multicenter study 
groups are the Children’s Cancer Study Group (CCSG), 
Intergroup Rhabdomyosarcoma Study (IRS), Inter- 
group Ewing’s Sarcoma Study (IESS), European Inter- 
group Cooperative Ewing’s Sarcoma Study (EICESS), 
European Osteosarcoma Intergroup (EOI) [41], Co- 
operative Osteosarcoma Study (COSS), Multi- 
Institutional Osteosarcoma Study (MIOS), several stud- 
ies of the International Society of Pediatric Oncology 
(SIOP), and several national groups. New chemothera- 
peutic schemes from these international study groups 
and the introduction of new drugs, such as cisplatin, 
ifosfamide and etoposide, resulted in further im- 
provements in the prognosis of patients, and especially 
of children with musculoskeletal malignancies. With the 
introduction of preoperative (neoadjuvant) chemother- 
apy, new prognostic factors became available; tumor 
necrosis after chemotherapy in osteosarcoma and 
Ewing’s sarcoma is a particularily important prognostic 
factor. 
Moreover, preoperative chemotherapy was able to 
reduce the tumor volume in a large number of cases and 
was an important prerequisite for preservative and limb 
saving surgery. In exceptional cases, tumor resection 
could be omitted after chemotherapy, because of com- 
plete necrosis of the tumor [42]. 
1.3. Improvements in radiation for musculoskeletal 
oncology 
The treatment of malignant bone tumors and soft tis- 
sue sarcomas requires a multimodal approach with 
carefully designed strategies. 
The results of radiation therapy improved due to 
more accurate information obtained by imaging techni- 
ques with contrast enhanced computed tomography and 
preferentially gadolinium enhanced magnetic resonance 
imaging [25]. 
Three-dimensional treatment planning and the use of 
conformal radiation therapy utilising multileaf col- 
limators increased the homogeneity of dose in the dif- 
ferent sections of the treatment volume and decreased 
the irradiated volume of the surrounding normal tissues. 
Intraoperative radiation therapy was developed and is 
nowadays under investigation, especially in comparison 
to external beam therapy. 
In Ewing’s sarcomas, the application of hyperfrac- 
tionated accelerated radiation therapy may contribute 
to a higher local control rate and myelo-ablative radio- 
chemotherapy may be advantageous in multifocal 
disease. 
In advanced osteosarcomas, the efficacy of new frac- 
tionation schemes combined with radiosensitizing drugs 
may be advantageous. 
For soft tissue sarcomas the benefit of interstitial 
brachytherapy in selected cases has been demonstrated. 
1.4. Surgical staging and functional evaluation 
Historically, an adequate surgical procedure has been 
the most effective means of treating the majority of 
musculoskeletal sarcomas. Nowadays chemotherapy 
alone is effective as a solitary treatment without surgery 
and/or radiotherapy in selective cases of childhood soft 
tissue tumor with histologically proven complete re- 
sponse [42]. In all other cases, chemotherapy has to be 
followed by extensive local treatment. Chemotherapy in 
combination with local radiotherapy and without surgi- 
cal tumor excision is only effective in a number of cases 
of childhood soft tissue tumors with good initial re- 
sponse and may be the only possible therapy in some 
cases of Ewing’s sarcoma with tumors inaccessible for 
surgical treatment. However, in most cases of musculo- 
skeletal sarcomas urgery remains the essential step in 
local and systemic tumor control. 
Many institutes around the world nowadays treat pa- 
tients with musculoskeletal tumors. In order to compare 
the results of treatment and to share the know-how it is 
obligatory to speak the same oncologic language. For 
this purpose a staging system is an important tool. It 
was William F. Enneking [43,44], who developed astag- 
ing system which primarily encompassed the biologic 
behavior of the tumor. This was a major step forward. 
The achievements of radiology and pathology played an 
important role in the system, but nowadays, with in- 
creasing impact, the improvements in tumor science are 
accomplished by cytogenetics, molecular biology and 
flow cytometry in addition to this staging system. 
The staging system guides the surgeon and the inter- 
disciplinary team to the best type of treatment for the in- 
dividual patient and it enables its supporters to 
communicate with one another, which obviously is the 
best way to improve the global results of treatment in 
musculoskeletal oncology. 
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In addition to the staging system, Enneking developed 
a system for the functional evaluation of patients who 
underwent limb saving surgery [45,46]. This system was 
adopted by those concerned with musculoskeletal 
tumors and is used all over the world. A way was found 
to discuss the outcome of limb salvage, which un- 
doubtedly in the future will improve the results of this 
type of treatment. 
1.5. The goal of limb salvage 
The goal of limb salvage in musculoskeletal oncology 
is the cure and the restoration of functional integrity of 
patients with a malignant tumor of bone or soft tissue 
by a combination of surgery and adjuvant therapy, 
without performing mutilating procedures. Amputation 
derived methods, like rotation plasty [47-491, should 
not be included. All methods of treatment hat avoid 
amputation, disarticulation or hemipelvectomy, without 
compromising the oncological result can be used to 
achieve the purpose of limb salvage. Limb saving sur- 
gery should not only pursue a good oncologic and func- 
tional result, but it should also strive after a good 
psychological outcome. 
In cases of soft tissue extension, limb salvage should 
only be recommended when resection of the tumor with 
optimal oncologic margins is able to preserve good func- 
tional results. 
2. In&cations for limb salvage 
The indications for limb saving surgery in 
musculoskeletal oncology refer to all malignant bone 
and soft tissue tumors of the extremities and axial skele- 
ton that are amenable to non-mutilating surgery. As the 
purpose of this type of treatment is the cure of the 
patient, one should definitely include the treatment of 
metastases of the primary tumor. 
Thus the indications for limb salvage [50,51] are: 
l Tumors which are located in the extremities and/or 
axial skeleton; 
0 Where optimal oncologic surgical margins are 
feasible; 
l Where the soft tissue extension is moderate; 
l Where the neurovascular bundles are not com- 
promised; 
l Where metastases are absent or amenable to opti- 
mal curative treatment; 
l In patients, who are in an optimal condition; 
l In whom there are no signs of infection; and 
l Who are capable of good cooperation during the 
treatment. 
From limb preserving surgery are excluded patients 
with sarcomas of the foot, large anaplastic sarcomas, re- 
currence following adequate resection, and with severe 
irradiation damage. Those patients are mostly best 
treated by amputation [52]. 
The fact that, for limb salvage, the neurovascular 
bundle should not be invaded by the tumor reflects the 
starting point that a limb without vessels and/or nerves 
cannot function on an adequate basis. It should, how- 
ever, be kept in mind, that there are some exceptions to 
this rule, for instance invasion involving the peroneal 
nerve and the anterior tibia1 vessels. Although a partial 
or total resection of the peroneal nerve will often result 
in sensomotory disturbances, it will not create complete 
disability and it therefore may be included in common 
practice of limb salvage. Sacrifice of the anterior tibia1 
vessels does not preclude restoration of function in pa- 
tients with tumors of the proximal tibia. Sacrifice of the 
sciatic or the median nerve would definitely prevent ade- 
quate recovery and therefore contaminations of these 
nerves are excluding criteria for limb salvage. 
Optimal surgical margins are 6 cm of normal bone 
around the bony margins of a bone tumor and 2 cm of 
normal soft tissue around its soft tissue extension 
[50,51]. In soft tissue tumors margins of 2-3 cm should 
be accomplished [53]. 
These margins are obligatory in tumors which are, at 
the time of surgery, highly aggressive and in which 
chemotherapy could not be instituted or which did not 
respond adequately to chemotherapy. If, however, a 
malignant umor appears to be sensitive to chemother- 
apy, one may accept smaller margins, for instance 3 cm 
of bone and 1 cm of soft tissues. However, the present 
diagnostic tools, including both radiological and 
histological methods, are not very reliable regarding the 
impact of chemotherapy on a tumor. 
A moderate soft tissue extension means that, after the 
resection of the tumor - with observations of the opti- 
mal margins - a restoration of active function is still 
possible. Reconstruction of a distal femur and knee joint 
in a patient in whom the active muscles have been 
resected is useless. This is an example of bad practice in 
limb salvage. In cases where metastases are present one 
should only consider limb saving surgery when, after 
chemotherapy and metastectomy, adequate tumor 
reduction and tumor necrosis has been demonstrated. In
all remaining cases of metastases one should not pursue 
limb salvage. Optimal condition, absence of infection 
and good cooperation of the patient are selecting cri- 
teria, which not only hold for the surgical part of the 
treatment, but also for chemotherapy. 
3. Type of treatment 
3.1. Role of grading and tumor biology 
In the treating team, a pathologist plays a central role 
in diagnostic and prognostic evaluation of musculo- 
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skeletal tumors [54]. His task is to classify and grade the 
tumors and to assess therapy effects if necessary [%I. 
Unfortunately, there is no grading system accepted 
world-wide, although the overall tendency is to employ 
a three-grade system, which is the most reproducible 
and the best way to predict survival [56,57]. Limitation 
of grading is connected with structural variations in dif- 
ferent areas of the same tumor. Grading can be 
misleading with tumors of uncertain histogenesis [56]. 
The predictive significance of various prognostic par- 
ameters varies in different types of musculoskeletal 
tumors [58-601. 
For soft tissue tumors the number of mitoses and 
extent of necrosis seem to be the most important para- 
meters in predicting biological behavior [56,61]. In limb 
preserving treatment inadequate surgical margins pre- 
dict for local recurrence, distant recurrence and overall 
survival [53]. Ancillary procedures such as special 
stains, electron microscopy and immunohistochemistry 
are essential in the tumor typing. In many cases electron 
microscopy is required particularly to differentiate be- 
tween sarcoma and malignant melanoma, malignant 
lymphoma or metastatic arcinoma as well as between 
various spindle cell or round cell tumors. The main 
limitation of electron microscopy as a diagnostic tool is 
connected with small sampling and paucity of specific 
ultrastructural features [56]. Immunohistochemistry 
permits high diagnostic accuracy, but achieved results 
must be interpreted in the context of light microscopic 
morphology to prevent interpretation errors [52]. Im- 
munohistochemical markers are not only used to detect 
cell lineage or tissue of origin of specific tumor, but also 
to assess malignant potential of neoplasms. Using anti- 
body Ki67 or staining proliferating cell nuclear antigen 
(PCNA), the proliferating activity in almost the entire 
cell cycle can be revealed and quantified [62,63]. Those 
methods are superior to histologically determined 
mitotic index, which is sometimes questioned for its 
insufficient reliability [52]. 
When the interdisciplinary treating team selects a 
particular therapy for a patient, it should not only take 
into account the radiological and histopathological fea- 
tures of the tumor, but also its response to neoadjuvant 
therapy [64] and its cytogenetic and flow cytometric 
characteristics. Many musculoskeletal tumors show 
clonal chromosomal abnormality, which will help to de- 
lineate several of these neoplasms [65]. Specific chromo- 
somal translocations of diagnostic significance were 
found in synovial sarcoma [66], myxoid liposarcoma 
[67], alveolar, undifferentiated and embryonal rhab- 
domyosarcoma [68,69], Ewing’s sarcoma, PNET, Askin 
tumor [70-721 and malignant fibrous histiocytoma 
[65,73-751. Ewing’s sarcoma, PNET and Askin tumor 
all show the same chromosomal error and this phenome- 
non may be indicative of similar biological behavior and 
common histogenesis [72,74]. Routine tumor typing and 
grading is mainly based on subjective interpretation of 
microscopical features and some inter-observer 
discrepancies in the diagnosis of musculo-skeletal 
tumors are well-known [52,76]. There is growing evi- 
dence that molecular pathological techniques can not 
only supplement conventional methods, but also im- 
prove tumor assessment providing objective informa- 
tion that cannot be obtained in any other way [77]. 
The treating team must be aware of the capabilities 
and limitations of a molecular approach to oncological 
diagnosis. 
Flow cytometric DNA analysis on fresh or paraffin 
embedded tumor samples is a reproducible and clinical- 
ly useful quantitative method characterizing malignant 
potential [78], although it does not allow clear separ- 
ation between benign and malignant tumors, and 
sporadically can demonstrate misleading results [52]. In 
musculoskeletal tumors it can be used as a reliable prog- 
nostic indicator, can follow the progress of disease and 
determine the effect of therapy [56,79,80]. There is a 
good correlation between grade and ploidy of soft tissue 
tumors [81]. Regardless of histogenetic type, it appears 
that benign and low grade malignant soft tissue tumors 
are diploid and high grade malignant umors in general 
are aneuploid [79] with the exception of epithelioid sar- 
coma [82]. 
DNA aneuploidy in musculoskeletal tumors is a 
strong independent negative prognostic factor 
[59,76,83,84]. 
DNA content and tumor size are also independent 
prognostic factors for metastases and can discriminate 
between patients with a good and with a poor prognosis 
after surgical treatment, and can help to select high-risk 
patients for further adjuvant therapy [76,83]. Recently a 
good correlation has also been found between 
cytogenetic abnormalities and DNA ploidy in benign, 
borderline malignant, and malignant soft tissue tumors 
[81,85]. 
No histological parameters predicted chemosensi- 
tivity in soft tissue tumors, and flow cytometric 
estimates of cell proliferation were the only pathologic 
features in initial biopsy that predicted subsequent 
response to chemotherapy [86]. 
In chondrosarcomas ploidy determination gives sig- 
nificant prognostic information even better than that 
obtained by conventional histological grading. Diploid 
chondrosarcomas show a significantly more favorable 
prognosis than hyperploid, which have been associated 
with early metastases and death [60,87]. The vast ma- 
jority of high grade osteosarcomas are non-diploid 
[59,84,85]. 
Present molecular methods used in oncology are 
expensive and time-consuming, but it can be expected 
that in the future technical improvement and 
automatization will simplify and increase the use of 
molecular diagnosis. 
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Gadolinium enhanced MRI [88] and magnetic reso- 
nance spectroscopy [89] are becoming valuable tools in 
determining the response of osteosarcoma to chemo- 
therapy. Positron emission tomography [90] may also be 
of value for evaluating tumor metabolism. These are ex- 
amples of diagnostic tools which increase insight into 
the biological behavior of a tumor. Each institute that 
treats patients with bone and soft tissue tumors should 
preside over divisions that are able to perform these 
diagnostic procedures. Perhaps one may conclude that 
centres that do not have access to the majority of these 
facilities, should not treat this type of patient. 
3.2. Role of surgical stage and biopsy 
It has been emphasized before that surgical staging is 
essential in order to treat a patient in an optimal way. 
Physical examination, laboratory studies and radio- 
logical evaluation including MRI are essential for this 
purpose. CT scanning of the lung is a valuable tool for 
detection of lung metastases in early phase. In highly 
vascularized tumors or in tumors of the pelvis one may 
consider angiography or digital subtraction angio- 
graphy. Also, in tumors of the pelvis, a urography may 
be helpful in delineating the ureter from the tumor. 
According to the Enneking staging system [43,44], 
malignant umors are graded by the histological pattern, 
the radiological appearance and the clinical course. Ad- 
vanced techniques, which give information on the bio- 
logical behavior of the tumor, should nowadays be 
included as well as biochemical analysis. Low grade 
tumors correspond with Broder’s class I and II, high 
grade tumors with Broder’s class III and IV. Intracom- 
partmental sites should be distinguished from extra- 
compartmental; this is essential in order to choose the 
proper margins at the time of operation. 
In the system, all tumors that develop metastases are 
graded in the same way. 
In addition to the grading of the tumor, the Enneking 
system also provides for a definition of the type of 
margin which is desirable or should be achieved at oper- 
ation. Four planes of dissection are distinguished 
[44,91], each of which gives a different result with re- 
spect to residual disease. As the Enneking system is by 
now in use all over the world, we will not go into any 
further detail. For those who are not familiar with this 
system however, we strongly advocate reading the refer- 
red papers. 
In almost all cases of bone and soft tissue malignan- 
cies, a biopsy [91-931 is taken somewhere along the 
preoperative tract. In the past, when amputation was the 
treatment of choice in these tumors, the site of biopsy 
was not always important. At present, knowing that 
70% of all malignant bone and soft tissue tumors can be 
treated by limb salvage, it is essential to choose the pro- 
per site of the biopsy [94]. The biopsy scar must be wide- 
ly excised with the specimen. The biopsy scar should be 
as small as possible in order to avoid a ‘waste of tissue’ 
resection, the biopsy should not contaminate the 
neurovascular bundle and haematoma should be avoid- 
ed [44,50]. The biopsy should be taken in line with the 
definite resection [93], which implies that it should be 
performed by the surgeon who will perform the resec- 
tion or excision. Frozen sections may be helpful to 
determine whether a representative viable tumor sample 
has been obtained for special procedures and to yield 
satisfactory permanent paraffin sections for interpreta- 
tion [93]. Cultures may be desirable in cases where infec- 
tion may be present [44]. Haematoma due to biopsy can 
be prevented by packing the biopsy tract with gel-foam 
or bone cement [44]. 
In some centers interest has been renewed in frozen 
section diagnosis followed by immediate surgery. Al- 
though its expected advantage is decrease of tumor 
dissemination and contamination if a tourniquet has 
been used, the increased survival after this procedure 
has not been proven [95]. 
There is a current trend to perform needle biopsies in- 
stead of an open biopsy. 
This strategy of performing needle biopsies is certain- 
ly valid for those who seek the optimal biopsy scar, in 
relation to the line of excision. Although in centres with 
a lot of experience with sarcomas, multiple core biopsies 
can often provide adequate diagnostic material, aspira- 
tion cytology is not sufficient [96]. It can be used, how- 
ever, in documenting recurrent or metastatic disease 
once a primary diagnosis has been established [57]. The 
amount of tissue which should be obtained from the bi- 
opsy should however correspond with the wishes of the 
pathologist and moreover with the need to perform 
more advanced tests like DNA flow cytometry, electron 
microscopy, application of cell markers and cytogenetic 
assays. All these methods are essential for a proper pre- 
diction of the biological behavior of the tumor and 
should not be hampered by a needle biopsy, which pro- 
vides an insufficient amount of tumor tissue. Pre-biopsy 
consultation of the pathologist, together with the atten- 
ding radiologist, may be of value in this respect. Such 
discussions often embark on the necessity to take biop- 
sies from one point of different bone and/or soft tissue 
parts of the tumor. 
3.3. Impact of combination therapy 
3.3.1. Chemotherapy 
Although the optimal chemotherapeutic s hedule in 
the treatment of Ewing’s sarcoma remains to be 
established, convincing data from the IESS-I study have 
shown the superiority of a four-drug regimen with vin- 
cristine, actinomycine D, cyclophosphamide and 
adriamycine (VACA) over a three-drug regimen without 
adriamycine in terms of event free survival (74% versus 
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54% EFS) and also the effectiveness of local control 
(96% versus 86%) [97]. Moreover, the IESS-II study 
demonstrated the superiority of high-dose VACA versus 
moderate-dose VACA [98]. The site of the tumor prov- 
ed to be of prognostic importance (distal versus prox- 
imal versus central) in the CESS-8 1 and the Italian study 
[99,100], and patients treated with chemotherapy, sur- 
gery and radiotherapy fared better than patients treated 
with surgery or radiotherapy in combination with 
chemotherapy [99-1011. However, the interpretation of 
the role of surgery compared to the role of radiation 
therapy with respect o outcome is difficult to assess due 
to the fact that smaller tumors which have a better prog- 
nosis are more amenable to surgery. 
Prognostic parameters in the CESS-81 study proved 
to be a tumor volume of < 100 ml (80% versus 32% EFS) 
and a good histologic response, i.e., less than 10% viable 
tumor cells detectable in the surgical specimen (79% 
versus 31% EFS) [99]. The CESS-86 study [loll 
demonstrated clearly that the introduction of ifosfamide 
(VAIA instead of VACA) was especially advantageous 
for large (> 100 ml) and central tumors with an EFS of 
43% in CESS-81 and an EFS of 67% in CESS-86. In this 
study tumor volume was no longer a risk factor. The re- 
sults of the two English trials also demonstrated a better 
outcome for all patients (including patients with 
metastases at diagnosis) treated with ifosfamide com- 
pared to cyclophosphamide (51% versus 34% EFS), 
however the outcome for patients with metastases at 
diagnosis and patients with central tumors was not 
statistically different [102]. Based on these CESS and 
UKCCSG studies with respect o the beneficial effect of 
ifosfamide, the new European EICESS-92 study is con- 
ducting a randomized trial in standard-risk patients 
(tumor volume < 100 ml) comparing VACA versus 
VAIA after 4 preoperative VAIA courses and local ther- 
apy. Based on a phase II study with ifosfamide and 
etoposide with significant responses even in children re- 
sistant to cyclophosphamide (1031, although not con- 
firmed by others in a non-randomized study [ 1041, 
high-risk patients (> 100 ml) in the EICESS-92 study are 
randomized to receive VAIA with or without etoposide. 
Preoperative chemotherapy has been used with in- 
creasing frequency in the management of patients with 
osteosarcoma in the past decades [ 105- 1081. A large 
number of international trials with a large variation of 
chemotherapeutic agents has demonstrated the efficacy 
of chemotherapy in patients with osteosarcoma 
[109,110]. The role of preoperative chemotherapy in 
osteosarcoma is especially important, because the 
biologic behaviour of this tumor causes it to be explicitly 
accessible for limb saving surgery [105]. In contrast to 
high grade primary osteosarcoma, the response to 
chemotherapy of postirradiation sarcoma is worse [ 1111. 
However, the amount of active drugs available for 
osteosarcoma is limited. Single-agent therapy with high- 
dose methotrexate, cisplatin, adriamycine or ifosfamide 
has resulted in over 20% partial and complete responses 
as proven in phase II trials (321. The role of high-dose 
methotrexate is controversial. Its efficacy was not con- 
firmed in a study using matched historical controls 
[ 1121, although this study used lower doses and a greater 
interval as advised by Rosen [13-15,108,113,114]. Dose 
intensity and/or serum levels of methotrexate have prov- 
ed to be of prognostic significance [115- 1171, although 
its efficacy as a solitary preoperative treatment was 
questionable [ 1171. The first European trial (EOI) com- 
paring cisplatin and adriamycine with this regimen plus 
high-dose methotrexate did reveal, however, that the 
disease-free survival was significantly higher in the two- 
drug arm, although overall survival was not [ 1181. The 
role of intra-arterial administration of cisplatin is still 
under debate [116,119-1211. 
Prognostic parameters have proved to be the alkaline 
phosphatase l vel [122], absolute tumor length of 10 cm 
[ 1231 or size of 100 cm* [ 1211, absolute tumor volume 
of 150 ml [123], and a good histologic response to 
chemotherapy in the surgical specimen [124,125]. The 
latter has been confirmed by many other studies. 
The role and dose intensity of adriamycine seems to 
be important [ 116,126,127]. The addition of ifosfamide 
to schemes consisting of adriamycine and high-dose 
methotrexate with or without cisplatin has proven to be 
effective, especially with regard to histopathologic re- 
sponse [1281. However, the combination with ifosfamide 
has its drawbacks because of its potential for adding to 
the nefrotoxicity of cisplatin [ 12 1,129]. Therefore, the 
value of dose intensity of the cisplatin-adriamycine 
scheme is currently being studied in the EOI. The value 
of altering chemotherapy in the postoperative period 
depending on the histological response to preoperative 
treatment is currently being investigated by the COSS 
group. 
The role of limb saving surgery in pediatric soft tissue 
tumor (especially rhabdomyosarcoma) extremity lesions 
is limited. Rhabdomyosarcoma extremity lesions are 
most frequently of alveolar subtype, occur in older 
children, and have a relatively bad prognosis. In most 
cases and studies diagnostic biopsy is followed by initial 
chemotherapy consisting of vincristine, actinomycine D 
and ifosfamide (VA1 or IVA) [ 130,13 l] or this combina- 
tion with adriamycine (VAIA) [132]. Primary, 
mutilative surgery is not customary in most studies and 
most frequently incomplete response to chemotherapy is
followed by radiotherapy [130-1321. However, the role 
of limb saving or more extensive secondary surgery 
should be reappraised, because verification by biopsy of 
complete clinical remission in cases not receiving 
radiotherapy could not prevent a high number of local 
relapses [133]. 
The efficacy of adjuvant chemotherapy in the treat- 
ment of soft tissue tumors of the extremities in adults is 
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doubtful, especially with regard to prolonged survival 
[ 134,135]. Ifosfamide and adriamycine appear to be the 
most active drugs with response rates of 24% [136,137]. 
Another drug with modest activity is dacarbazine 
(DTIC) with a response rate of about 17% [ 138,139], 
almost exclusively used in combination chemotherapy. 
Promising results have been reported on the treatment 
of (recurrent) soft tissue sarcomas in the extremities by 
isolated perfusion of the limb with melphalan, tumor 
necrosis factor and interferon gamma [ 140,141]. A fur- 
ther development, not necessarily restricted to soft tissue 
sarcomas in the extremity, may be intra-arterial infusion 
with cisplatin. 
3.3.2. Radiation therapy 
3.3.2.1. Radiation therapy of bone tumors. Techni- 
ques and treatment volume. Radiation therapy of malig- 
nant bone tumors requires meticulous planning. Exact 
knowledge of tumor localization, of macroscopic tumor 
extent and of all tissues at risk of microscopic disease is 
essential to define the clinical target volume. This infor- 
mation is obtained by clinical examination, MRI and, if 
available, the resected specimen. The design of a 
reproducible and comfortable patient set-up with the aid 
of immobilization devices such as vacuum pillows and 
casts, is necessary. 
Decisions have to be made about the choice of radia- 
tion technique (external beam, intraoperative therapy or 
brachytherapy), radiation beams and beam modifiers 
(wedge filters, compensators). A CT scan at the therapy 
stage can be helpful in determining the choice of radia- 
tion beams. 
In the first phase of treatment the clinical target 
volume consists of macroscopic tumor and a margin for 
microscopic disease. If the medullary cavity of the bone 
is involved, the radiation volume includes the whole 
bone, with attention to the epiphysis in young children. 
The epiphysis distal to the tumor may be spared if a 5- 
cm margin can be assured. In the second phase of treat- 
ment a boost of radiation is given to the area of 
macroscopic disease. In extremities a strip of tissue 
should be spared to keep the lymphatic system func- 
tioning. 
Ewing’s sarcoma. Radiation therapy has played the 
major role in obtaining local control in Ewing’s sar- 
coma. However, since the successful adoption of chemo- 
therapy with increasing evidence of it prolonging 
disease-free survival, the still relatively high rate of local 
failure following radiation therapy has become evident 
[142,143]. In view of the increased risk of local failure 
with increasing size of the primary tumor, a large bulky 
tumor should be considered a relative contraindication 
to radiation therapy alone to obtain local control 
[99,144,145]. 
Analysis of patients in the Intergroup Ewing’s Sar- 
coma Study and in other clinical investigations did show 
that the tumor volume is prognostically important [146]. 
The current treatment protocols for Ewing’s sarcoma 
often begin with 3-5 cycles of induction chemotherapy. 
After that, depending on tumor response, the local treat- 
ment consists of surgery combined with irradiation or 
radiation therapy alone. Initial results of the Pediatric 
Oncology Group study showed no advantage for whole- 
bone irradiation compared with tailored portal irradia- 
tion [147]. 
In 1992 the European Intergroup Ewing’s Sarcoma 
Study initiated a phase III study. In this multicenter 
trial, among other things, the impact of surgery and two 
types of radiation therapy on local control, overall sur- 
vival and morbidity will be evaluated after 4 courses of 
induction chemotherapy. Radiation therapy is given in 
conventional daily fractions or as hyperfractionated ac- 
celerated split course radiation. 
The indications for postsurgical radiation therapy and 
the recommended oses depend on the Enneking 
classification of the surgical intervention and the 
histological response of tumor following chemotherapy. 
These indications are intralesional surgery (55 Gy), and 
marginal surgery with a poor response to chemotherapy 
(55 Gy), marginal surgery with a good reponse (45 Gy), 
and wide resection with a poor response (45 Gy). After 
a wide resection and a good response to chemotherapy 
and after radical surgery radiation therapy is not recom- 
mended. 
For patients with an early local or multifocal recur- 
rence or multifocal disease at diagnosis, investigations 
with respect o the use of autogenous or allogeneic bone 
marrow transplantations after myelo-ablative radio- 
chemotherapy are in progress (NCI, CESS). 
Osteosarcoma. At present he best standard treatment 
for osteosarcoma is the combination of systemic hemo- 
therapy and surgical resection [ 148- 1501. 
Radiation therapy is only applied for patients requir- 
ing palliation for advanced, inoperable tumors of ex- 
tremities, pelvis and axial sites. 
The palliative radiation dose has to be up to 70-80 
Gy in 7-8 weeks at 10 Gy each week, but this dose has 
to be adapted to the tolerance dose of surrounding nor- 
mal tissues. 
A possible novel approach is the combination of high- 
dose-per-fraction irradiation with intra-arterial 5- 
bromodeoxyuridine as a radiosensitizer, and simulta- 
neous infusions of methotrexate-leucovorin. This 
scheme has resulted in high normal tissue toxicity [ 15 1). 
Other investigators used high-dose radiation therapy 
together with intravenous iododeoxyuridine or 
misonidazole as radiosensitizer and chemotherapy 
resulting in 75% local control [ 1521. New fractionation 
schemes and radiosensitizing drugs, or both, should be 
considered. 
3.3.2.2. Radiation therapy of soft tissue sarcomas. 
Local control can be achieved by radiation therapy 
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alone, bslt it requires extremely high doses of radiation 
and leads to a high risk of side-effects [153,154]. In 
several studies it was also shown that the local control 
rates achieved with radiation alone were inferior to 
those obtained with surgery and that local control was 
dependent primarily on the volume of the local tumor 
[155]. 
For these reasons, radiation therapy alone in the man- 
agement of soft tissue tumors is a second choice for pri- 
mary curative treatment and is mostly reserved for 
palliative treatment. It is limited to patients who have 
locally advanced, inoperable, recurrent, or metastatic 
disease, and patients who refuse surgery. 
The main indication for radiation therapy is as adju- 
vant therapy to surgery. The rationale for this combina- 
tion is to restrict surgery and add moderate-dose 
radiation in order to preserve cosmesis, anatomy and 
function of the extremity involved. Surgery removes the 
bulk of the tumor and radiation therapy is used to inac- 
tivate microscopic disease involving the surrounding 
tissues. 
3.3.2.3. Radiation techniques. As standard procedure, 
a shrinking-field technique is applied with two or three 
phases. In the first phase of radiation treatment, the 
whole anatomic compartment is treated using large 
fields. This requires often complex treatment planning, 
field adaptations by individual blocks, and the use of 
wedge filters and tissue compensators. 
Adequate beam configurations have to be determined 
to avoid irradiation of uninvolved muscle compartments 
and bone. In extremities a strip of tissue should be 
spared to keep the lymphatic system functioning. The 
radiation dose is 50 Gy, given in daily fractions of 1.8-2 
Gy, five times per week, with all portals treated every 
fraction. 
In the second phase, the clinical target volume is 
reduced to the original tumor bed with 2-cm margins, 
and an additional 10 Gy is given in daily fractions of 
1.8-2 Gy. Often a bolus is used to bring the dose given 
to the surgical scar up to 60 Gy. If surgery is not radical 
and macroscopic disease is left, then the third phase 
follows with an extra tailored fractionated boost dose of 
10 Gy. 
This standard shrinking field technique concerns ex- 
ternal beam irradiations with photons or electrons. In 
some cases special techniques may be used like proton 
therapy, intraoperative lectron beam [ 156- 1581 and in- 
terstitial brachytherapy [159,160]. 
In combined treatment, radiation therapy can be ad- 
ministered preoperatively, intraoperatively or 
postoperatively. 
Preoperative radiation therapy. This technique has 
several theoretical advantages: (i) the clinical target 
volume can be limited to the clinically and radiologically 
demonstrated tumor and the surrounding tissues at risk 
of microscopic disease because no surgically 
manipulated tissues are present; (ii) the mass of the 
tumor after radiation may become smaller by the time 
of surgery and that may facilitate resection; (iii) inacti- 
vation of tumor cells by radiation may decrease the risk 
of tumor implantation and embolization during surgery; 
and (iv) an irresectable tumor mass may become respec- 
table after radiation therapy. 
Several studies showed that planned preoperative ra- 
diation therapy in patients with histological high grade 
sarcomas can have good results [ 17,16,16 1,162]. 
Zntraoperative radiation therapy. Intraoperative radia- 
tion therapy is given during surgery mostly as a high sin- 
gle dose of electron beam irradiation to the tumor bed 
after moving normal tissues out of the radiation field. 
The electron energy varies from 9 to 18 MeV depending 
on the required depth of penetration. The dose of lo-20 
Gy depends on the anatomical site and on field size. It 
is usually combined with fractionated external beam 
therapy. In most studies tumors in the retroperitoneum 
were involved. The benefit of intraoperative radiation 
therapy in terms of local control and disease free survi- 
val is still not clear, when compared to pre- or postoper- 
ative external beam radiation therapy [156-1581. This 
technique is still under investigation. 
Postoperative radiation therapy. In most institutions 
postoperative radiation therapy is used [ 17,163,164]. 
The advantages of postoperative radiation compared to 
preoperative are: (i) complete information regarding the 
exact extent, localization, histologic grade and resection 
margins of the tumor is available for determination of 
the clinical target volume; (ii) decreased risk of wound 
healing complications; and (iii) no delay of resection. 
The presence of the following are indications for post- 
operative radiation therapy: all histological high grade 
tumors; all recurrences, even when surgery is radical; 
spill during surgical intervention; irradical surgery when 
reexcision is not possible or too mutilating; resection 
with a margin < 2 cm; and reexcision following incom- 
plete surgery if the whole surgical area is not resected. 
In principle, the clinical target volume for postoperative 
radiation therapy includes the original tumor volume, 
possible subclinical or microscopic extensions and con- 
taminated areas due to surgery, for example the site of 
drain and haematoma. 
This clinical target volume should be defined by phys- 
ical examination, information obtained from 
preoperative imaging studies (CT, or preferably, .MRI), 
the extent and method of surgery, size and histological 
grade of the tumor. 
The following guide-lines can be advised: 
(i) The clinical target volume for intracompartmental 
tumors is the whole compartment concerned. 
(ii) The margin for extracompartmental high grade 
tumors in the first phase is 7- 10 cm, taking the anatomi- 
cal boundaries into account. For the extremity, these 
anatomical boundaries are determined by interosseus 
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membranes, major facial planes or bones. For low grade 
tumors the margin is 5-7 cm. Regional lymph nodes are 
usually not treated, but such treatment has to be con- 
sidered in the case of synovial or epitheloid sarcomas. 
(iii) In the second phase, the clinical target volume for 
the boost dose is the volume of the original tumor with 
a margin of 2 cm. 
(iv) After an unradical resection, third phase, the 
maximum dose is given to the preferably radio-opaque 
clipped remaining tumor area with a margin of 1 cm. 
Interstitial bruchytherapy. Interstitial brachytherapy 
with iridium- 192 or iodine- 125 sources can be used in se- 
lected cases to boost the tumor bed in combination with 
external beam therapy [ 159,160]. Plastic tubes are plac- 
ed at l-cm intervals surrounding the target volume at 
the time of surgery and the target area is marked with 
radio-opaque clips for dosimetric alculat’ions. Tempo- 
rary implants are employed using after-loading techni- 
ques. This mostly has consisted of a single-plane 
implant. Reduction of the high rate of wound healing 
complications has been achieved by postponing the 
loading of radioactive sources until after the fifth post- 
operative day [ 1601. 
3.3.3. Surgical adjuvant therapy at the time of operation 
3.3.3.1. Cryosurgery. Cryosurgery, the spraying of ni- 
trogen liquid at - 19O”C, may sometimes be indicated in 
certain cases of malignant bone tumors. The method 
was developed by Marcove [165] in the early seventies, 
and was especially advocated for aggressive benign 
tumors, like giant cell tumor or chondroblastoma. In 
some low grade malignant umors, located in sites where 
wide excisions margins would induce major disability, 
this method of treatment should be considered. Scien- 
tific arguments for these statements are based on studies 
by Malawer [166]. Examples of this combination are: 
chordoma of the sacrum and low grade malignant 
tumors of the vertebral body. In principle the lesion is 
excised with an intracapsular or marginal margin and in 
addition liquid nitrogen is poured or sprayed into the 
resection cavity. As the method respects anatomic lines, 
it certainly can be part of limb saving surgery. In some 
rare cases the method is also used as a last resort pallia- 
tion method, for instance in osteosarcoma of the verte- 
bral column or sacrum, where neither chemotherapy nor 
radiotherapy could accomplish a reduction of the 
tumor. In our experience this method has proven its 
value in special cases as outlined above. 
3.4. Site of the primary tumor 
We will now discuss the actual surgery, where the limb 
salvage takes place. For the purpose of clarity, this 
chapter is divided into three sections, covering the upper 
extremity, the axial skeleton including the vertebral col- 
umn and the pelvis, and finally the lower extremity. In 
each section the consequences of excision and resection 
will be outlined and options for reconstruction will also 
be mentioned. 
3.4.1. Upper extremity 
All resections should be performed according to the En- 
neking staging system [43,44], which implies adequate 
surgical margins in accordance with the biological 
characteristics of the tumor. If these margins cannot be 
obtained without compromising the optimal oncologic 
strategy, an amputation or disarticulation should be per- 
formed. 
In tumors of the hand, ray excision may be a feasible 
procedure. Reconstruction is seldom required or possi- 
ble. In tumors of the wrist [167] local en bloc excision 
is sometimes possible. Reconstruction in these cases may 
be accomplished by implantation of an endoprosthesis 
[168] or even an allograft, in order to give mobility to 
the joint. However these methods often fail and therefore 
a more biological reconstruction should be preferred, for 
instance with the aid of a vascular&d fibula [169] or il- 
iac bone transplant. In these cases the reconstruction is 
identical with an arthrodesis of the wrist. 
Due to the closeness of important neurovascular struc- 
tures, tumors of the forearm and elbow are seldom ac- 
cessible to limb saving surgery. If an excision or resection 
with adequate margins is possible, reconstruction may be 
considered with an allograft or endoprosthesis. From a 
functional point of view, an arthrodesis for the elbow is 
not a feasible alternative. Endoprosthetic reconstruction 
in the area of the elbow joint will in the long term be sub- 
ject to loosening, and reconstruction with an allograft may 
be complicated by the development of pseudoarthrosis 
between the host bone and the graft, infection and 
fracture. 
Many tumors of the upper extremity are located in the 
humerus, especially the proximal metaphysis and 
diaphysis. Often resection in this area can be performed 
with adequate margins. Reconstruction may be ac- 
complished with an endoprosthesis [ 1701, allograft or 
vascular&d fibula (Fig. 1). These methods guarantee a 
good turning point for the elbow and forearm. However 
in most cases active shoulder function is restricted due 
to the amount of soft tissue resection. Because the 
humerus is not a weight bearing bone, most types of 
reconstruction, both intercalary, osteoarticular and en- 
doprosthetic survive for a long time. For many years 
tumors of the scapular region and shoulder joint itself 
could not be removed without sacrifice of the upper limb. 
However since Tikhoff and Linberg [171] described the 
procedure which was named after them, and since the fur- 
ther development of this procedure by Malawer [172], 
tumors in this region are often amenable to limb saving 
surgery. After partial resection of the scapula nd the pro- 
ximal humerus, a flail upper arm is prevented by 
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Fig. 1. (a) IB chondrosarcoma of the proximal humerus. (b) Same patient, after incorporation of the graft. 
reconstruction with an endoprosthesis or allograft which 
is fixed between the remnants of the scapula and the 
humerus. Although normal shoulder function is never ob- 
tained, the cosmetic result of the shoulder is good as well 
as the functional results of the elbow, forearm and hand. 
Sometimes even the whole scapula is removed in this 
procedure. A Kin&her rod may then provide for the 
bridging of the defect between the humeral diaphysis and 
the thoracic wall. Complete resections of the scapula have 
been reconstructed by implantation of an endoprosthesis. 
These reconstructions are still experimental and should 
not be regarded as common limb saving practice, although 
the results, according to Eckardt [ 1731, are promising. 
3.4.2. Axial skeleton 
3.4.2. I. Vertebral column. The vertebral column is cer- 
tainly one of the areas in musculoskeletal oncology where 
limb salvage is hardly a feasible option, due to the 
closeness of important neural and vascular structures. 
Although resection in malignant umors can sometimes 
be performed with adequate margins [174,175], this often 
only pertains for small tumors in this region. In these cases 
reconstruction may be obtained with allograft bone, 
spinal instrumentation or even endoprosthetic replace- 
ment. However, in our view, after adequate resection, 
reconstruction i this area should preferably be performed 
on a mainly biological base, for instance with autogenous 
vascularized bone and spinal instrumentation. A 
biological reconstruction will reduce the risk of complica- 
tions in the long term and this is an important feature 
especially in the spinal region. All secondary operations 
will again endanger vital structures of the spinal canal and 
its surroundings. 
3.4.2.2. Pelvis and sacrum. In the field of limb salvage, 
tumors of the pelvis and sacral areas are the most 
challenging [176]. The main reason for pursuing limb 
salvage in these areas [177], is the fact that hemipelvec- 
tomy and sacrectomy are mutilating procedures, both 
somatically and psychologically. Due to the usually large 
size of these tumors (1781, large resections of bone and 
soft tissue are often necessary in order to obtain adequate 
surgical margins. This is the main reason why limb salvage 
in these areas often does not yield an acceptable func- 
tional result [ 1791. 
Critical structures which should not be involved or con- 
taminated in order to preclude limb salvage are: the sciatic 
and femoral nerve, the iliac and femoral vessels and a ma- 
jor portion of the gluteal muscles and the surrounding 
soft tissues. 
According to Enneking [ 1801, three types of resection 
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may be distinguished with respect o the pelvis: I. Iliac 
(IA: including the gluteal muscles); II. Peri-acetabular 
(IIA: including the hip joint); and III. Ischiopubic. 
In type I resection the hip joint is preserved and restora- 
tion of the pelvic ring can be accomplished by bone grafts 
interpositioned between the sacrum and the iliac rem- 
nants. A vascular&d fibula graft suits this purpose well 
[181]. Allografts or endoprostheses should not be used. 
In most cases of type II resection - provided that one 
has to deal with a malignant tumor - the entire 
acetabulum has to be resected. This situation presents a 
challenge for reconstruction. Only in the almost 
hypothetical situation that resection of only one third of 
the acetabulum isrequired, is reconstruction ot necessary 
[ 1781. After peri-acetabular resection several options are 
available regarding reconstruction [ 1821. An iliofemoral 
arthrodesis [176,179,183] (Fig. 2) often ends up in a 
pseudoarthrosis, and the iliofemoral pseudoarthrosis 
should be compared functionally to a flail hip. An 
ischiofemoral rthrodesis often takes the same track [ 1841 
and as a result most patients who undergo either an il- 
iofemoral or an ischiofemoral arthrodesis end up with a 
leg length discrepancy, use one or two crutches and lack 
stability of the hip joint. A successful arthrodesis may be 
accomplished in 42% of the patients [ 1761. 
Alternatives are the use of an allograft, an endo- 
prosthesis or a composite of both [183]. 
The results of reconstruction with an allograft are con- 
fusing [ 179,185,186]. Some authors mention good results, 
others stress the risks of non-union, hampering the pro- 
cess of revitalisation, and finally conclude that allograft 
reconstruction should still be regarded as experimental 
[179,185- 1871. Late fractures and the occurrence of a 
Charcot joint are important features, in addition to 
degenerative changes in a transplanted hip joint. 
An endoprosthesis could be chosen as a reasonable 
alternative. The options are a pelvic prosthesis (Fig. 
3a-c), including a hip joint [ 182,188,189], or a saddle pro- 
sthesis [190,191] (Fig. 3d). Although the restoration of 
the pelvic ring is often accomplished by a pelvic pro- 
sthesis, the results of this type of reconstruction are often 
poor, due to the soft tissue deficiency or the occurrence 
of loosing, with or without infection. This also applies 
for the composites, which consist of a pelvic allograft and 
a prosthetic total hip replacement. 
The saddle prosthesis may yield a smaller isk of com- 
plications. After its introduction in 1982, it has been us- 
ed in increasing numbers with success world-wide. 
In all types of peri-acetabular reconstruction general 
complications are to be expected: infections, skin necrosis, 
neurovascular lesions and large haematoma 
[176,178,184,192,193]. The more complex the method of 
reconstruction, the greater the risk of complications. The 
frequency of these complications varies from 20 to 65%. 
Type III resections generally do not require reconstruc- 
tions [178]. The pelvic ring may be interrupted, but this 
does not impose extraordinary stress forces on the hip 
or sacroiliac joint. 
A combined I-II-III resection however presents a ma- 
jor challenge for reconstruction. Reconstruction in this 
situation requires the utmost ingenuity of the surgeon and 
engineer. A sacrofemoral fusion with the aid of a 
vascularized graft may be chosen [193], but, after a long 
period of immobilisation the patient often ends up with 
a leg length discrepancy and the graft is also at major risk 
of fracture. 
A hemipelvic allograft, combined with a hip en- 
doprosthesis, i  an alternative with many risks, as has been 
mentioned before [ 1931. 
After a combined II-III resection, the reconstruction 
essentially does not differ from that following a type II 
resection. Methods of reconstruction are an iliofemoral 
arthrodesis or pseudoarthrosis [7], an allograft or a sad- 
dle prosthesis [1941. Even a flail hip may be acceptable. 
After a combined I-II resection, reconstruction may be 
performed by a fusion between the ischium and the femur 
or between the ischium and the sacrum with the aid of 
the partially transposed ipsilateral proximal femur. An 
endoprosthesis consisting of a custom-made acetabulum 
bearer and a proximal femur prosthesis could provide for 
mobility and restoration of the junction between the re- 
maining part of the ipsilateral femur and the reconstructed 
hemipelvis [194]. This method of reconstruction is still 
experimental and has a high risk of complications. 
Resections of the sacrum are almost inevitably linked 
to neurological deficits and loss of stability 1195-1971. 
According to Enneking, wide margins may be achieved 
during resection of the entire sacrum with ‘acceptable’ 
deficits, but radical margins will often result in a hemicor- 
porectomy. A wide resection is often associated with the 
occurrence of incontinence, paraplegia and impotence. 
Reconstructions in these cases are experimental; their 
main purpose is to refixate the iliac bone to the vertebral 
column [198]. 
Seldom can a unilateral sacral resection of a tumor be 
achieved with wide margins. Due to the presence of the 
remaining contralateral sacrum, the neurological deficits 
may be less important. 
3.4.3. Lower extremity 
The thigh, the upper part of the leg and the distal part 
of the femur, are the parts of the body where limb saving 
surgery was attempted for the first time [3,5]. Due to the 
fact that tumors in these areas often manifest in an early 
phase and that an abundant amount of soft tissue is usual- 
ly present, limb salvage often succeeds with a good result 
both oncologically and functionally. Limb salvage was 
first attempted in the area of the thigh (Fig. 4), but 
nowadays complete resections of the femur, hip and knee 
joint, as well as combined distal femur and knee resec- 
tions (Fig. 5), are common practice in this field of surgery. 
Of course the rules, which were outlined above (Section 
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Fig. 2. (a) In chondrosarcoma of the periacetabular egion. (b) At tempted iliofemoral arthrodesis after wide resection. (c) Iliofemoral 
pseudarthrosis after failed arthrodesis. 
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Fig. 4. (a) IIB osteosarcoma of the proximal femur, with secondary ABC. (b) Reconstruction after Rosen T7 protocol and marginal uncon- 
taminated resection with proximal femur/hip prosthesis after IO years. 
2), must be taken into account, but this can easily be done. 
Reconstructions can either be performed with allograft 
bone or mega-endoprosthetic replacements [ 168,170] or 
with vascular&d bone grafts [ 169,199,200]. In general 
the surgeon will pursue active mobility of the artificial 
joint, but under special circumstances, especially in the 
area of the knee, a resection arthrodesis may be the best 
solution. As an alternative to allograft or endoprosthetic 
reconstruction i tcrcalary diaphyscal reconstruction may 
be performed with a combination of autogenous bone and 
a Kiintscher rod (Fig. 6). 
Either vascularized or non-vascularized fibula bone or 
tibial chips can be used in this respect. In children 
reconstruction with an allograft or conventional mega- 
endoprosthesis will eventually result in a leg length 
discrepancey. This complication can be prevened by the 
use of an invasive [201-2031 or non-invasive [204-2061 
adjustable lengthening prosthesis. 
Fixation of the implants or grafts can be achieved in 
different ways. Mega-endoprostheses may be fixed with 
or without cement. Essentially the debate concerning the 
choice does not differ from the one which is still going 
on with respect o ordinary artificial joints, like total hip 
and knee replacements. Allografts may be fixed with 
plates and screws or with an intramedullary nail. In Sec- 
tion 5 we will detail the advantages and disadvantages 
of both methods. Leaving aside the assumption that an 
allograft will revitalisc ompletely, the discussion concer- 
ning the fixation methods refers to the way in which in- 
corporation of the allograft occurs. Those who believe 
in an endosteal pathway most probably will use a plate 
and screws, and those who choose a periosteal pathway 
will use an intramedullary nail. 
Both endoprosthetic and allograft reconstruction will 
eventually lead, after either a few or many years, to com- 
plications, a situtation the surgeon has to deal with 
[ 194,207]. These problems will be outlined in Section 5. 
Due to its lack of soft tissues the upper part of the lower 
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Fig. 5. (a) MRI of IIB osteosarcoma of the distal femur, with 
pathological fracture. (b) Reconstruction with distal femur/knee n- 
doprosthesis after Rosen Tts protocol; >90% necrosis, wide 
resection. 
leg is difficult to reconstruct. Tumors in this area are 
rather frequently amenable to limb saving surgery. 
However, due to the anatomical circumstances, the main 
neurovascular bundle is more frequently compromised 
than for instance in the distal part of the upper leg. If 
resection of a tumor in the proximal part of the lower 
leg is possible, reconstruction presents two important 
challenges [208]. First, the refixation of the patellar ten- 
don in order to restore active function to the quadriceps, 
and second, the coverage with soft tissue of the 
reconstructed area at the ventral side. This especially 
holds true for reconstructions which enable active mobili- 
ty of the knee joint. Usually a resection of a tumor of 
the proximal part of the lower leg includes the knee joint. 
In endoprosthetic replacements he megaprosthesis will 
include a diaphyseal-metaphyseal replacement and an ar- 
Fig. 6. (a) IIB osteosarcoma of the distal femur, with involvement of 
the knee. (b) Wide extra-articular resection after chemotherapy, 
followed by arthrodesis with implant. 
titicial knee joint. In the early years of limb salvage, 
allograft reconstructions were performed which replac- 
ed the resected area, but the reconstructions resulted in 
many complications, such as fractures of the bone, 
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osteoarticular dysfunction and insufficiency of the 
ligaments. Therefore, this type of reconstruction should 
no longer be regarded as a feasible option. 
At present most reconstructions are performed with the 
aid of an endoprosthesis [208] or a composite consisting 
of an endoprosthesis and an allograft [209]. Advocates 
of the latter arrangement claim that the patellar tendon 
can be fixed more easily to the allograft tibia1 replace- 
ment, which is fixed to the endoprosthesis by the in- 
tramedullary stem of the prosthesis. But this type of 
reconstruction meets the same soft tissue deficits as the 
reconstruction with a mega-endoprosthesis alone. The 
major step forward in dealing with this problem was pro- 
posed by Malawer [210] who advocated the use of the 
medial head of the gastrocnemeus muscle, leaving its 
vascular bundle intact. 
The transposed muscle covers the upper anterior part 
of the reconstructed area and thus provides for adequate 
soft tissue coverage. The patellar tendon can easily be 
sutured to the transposed muscle, thus creating a 
biological part of the whole reconstruction. Other 
methods have been described for this purpose [211], but 
to our knowledge the gastrocnemeous transposition serves 
the goal in the best way. 
We would like to emphasize that all tumors that have, 
or most probably have, contaminated the knee joint 
should be treated with an extra-articular esection. This 
means that the tumor and the knee joint is resected en 
bloc with adequate margins. Inadequate margins will 
often result in local recurrence and this should be avoid- 
ed in all circumstances. An extra-articular resection could 
be reconstructed with a resection arthrodesis as has been 
mentioned above. 
Sometimes resections and excisions in the area of the 
knee joint include the removal of essential parts of the 
extensor mechanism. In order to restore the strength of 
the extensor mechanism transposition of flexors has been 
performed, e.g., the biceps femoris or semitendinosis. As 
the strength of transposed muscle diminishes by 30% and 
as the operation field has to be extended -which might 
increase the risk of infection - a transposition should 
only be performed after thorough consideration. One 
should keep in mind that the effect of muscle transposi- 
tion is still under discussion with regard to expected 
enhancement of muscle strength [212]. 
The lower leg, ankle joint and foot are hardly ever sub- 
ject to limb saving surgery. Adequate margins around 
tumors in these areas preclude feasible bony or prosthetic 
replacements and fixation, and also the lack of soft tissues 
make coverage almost impossible. One exception is 
perhaps when there is a small low grade tumor in the 
vicinity of the ankle joint, where an arthrodesis might 
serve as an acceptable method of reconstruction. 
4. Results of limb saving surgery 
The results of limb salvage should be judged both on 
an oncological base and on the functional outcome. As 
outlined in Sections 1.5 and 2, the oncological goal of limb 
salvage should be the complete cure of the patient. The 
functional goal is to restore the integrity of the part of 
the body which is involved in an optimal way. 
4.1. Oncological results 
From the very beginning the tumors considered to be 
amenable to limb saving surgery were osteosarcomas nd 
chondrosarcomas. Much debate has concerned the dilem- 
ma of whether limb salvage was equivalent o amputative 
surgery from an oncologic point of view. In 1984 a con- 
sensus meeting [213] was held at the National Institute 
of Health (USA), during which the conclusion was reach- 
ed that limb saving treatment was equal to amputative 
surgery in patients suffering from osteosarcoma or soft 
tissue sarcomas, provided that the guidelines as outlined 
in Section 2 were taken into account. At present his state- 
ment also applies to other tumors like chondrosarcoma, 
Ewing’s sarcoma, malignant fibrous histiocytoma, 
adamantinoma of long bones, synoviosarcoma, etc. 
Seventy percent of the patients uffering from a malig- 
nant bone or soft tissue sarcoma can nowadays be treated 
with limb saving surgery without compromising the on- 
cologic result [ 106,168,170,2 141. For osteosarcoma this 
includes a live-year survival rate of 60% and for Ewing’s 
sarcoma the figure is almost similar. It should be stress- 
ed however that these figures reflect the average presen- 
tation of the tumors. Pelvic and sacral tumors certainly 
have a worse prognosis compared to tumors of the prox- 
imal or distal femur. This is due to the fact that at the 
time of detection most tumors of the pelvis have extend- 
ed so deeply into the surrounding tissues that adequate 
surgical margins cannot be achieved. With respect o Ew- 
ing’s sarcoma, it should be emphasized that a relation- 
ship seems to exist between the overall survival rate and 
the volume of the tumor; a tumor smaller than 100 cm3 
would correlate with a more favorable prognosis. 
4.2. Functional results 
The need for uniform guidelines for functional evalua- 
tion of limb saving surgery was expressed by Eckhardt, 
Sim and Enneking at the first international symposium 
on limb salvage in Rochester, USA in 1981. Enneking 
presented the first draft of the guidelines at the second 
symposium in Vienna, 1983. The system, adapted in the 
following years, was adopted by the Musculoskeletal 
Tumor Society (MSTS), and was published in 1993 by 
Enneking, Dunham, Gebhardt, Malawer and Pritchard 
1461. The combination of authors not only suggests a wide 
support within the USA, but the adoption by the MSTS 
urges all institutes around the world performing limb 
salvage to use it [168,170,207,215]. 
In brief the system assigns numerical values (O-5) to 
6 categories; pain, functional emotional acceptance for 
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either extremity; support and walking ability plus gait be- 
ing specific for the lower extremity, and finally hand posi- 
tioning plus lifting ability being specific for the upper 
extremity. As results must be presented world-wide in a 
comparable way, all limb saving institutes hould use this 
system. The authors feel that a survey of functional results 
which can be expected or achieved in certain areas is not 
possible. Not only the site of the tumor is important; its 
extension is especially important, and this varies from 
tumor to tumor. In general one could say that the best 
results are obtained in the areas of the hip and knee joint 
followed by the shoulder and proximal tibia. Pelvic and 
sacral tumors will obviously close the list. 
5. Complications of treatment 
5.1. Surgical complications 
In medicine and surgery almost all advanced new 
techniques result in complications. Limb saving surgery 
is not an exception [214]. The magnitude of the complica- 
tions is related to the site and the extension of the surgery, 
the overall and local conditions of the patient and the im- 
pact of adjuvant herapy. The surgical complication with 
the greatest impact is local recurrence. Local relapse of 
a tumor should be avoided in all circumstances. As long 
as the surgeon sticks to the rules of the Enneking staging 
system, the risk of a local recurrence is small, perhaps 
about 5% [216]. The danger of limb salvage is that the 
surgeon gives more attention to the reconstruction than 
to the oncologic resection. 
One should not compromise oncological margins in 
order to preserve sufficient issue suitable for reconstruc- 
tion, as this will obviously enhance the risk of local recur- 
rence. Unfortunately this attitude was taken by many limb 
saving institutes in the late 1980s [187,2 171, and as a con- 
sequence the local recurrence figures rose world-wide to 
lo-14%. In this respect it should be mentioned that the 
risk of local recurrence after pelvic surgery rose to 50% 
[176,184]. 
If an adequate resection of a tumor can be accomplish- 
ed just by removal of bone and/or joints, the presence of 
a sufficient amount of soft tissues will reduce the risk of 
complication after reconstruction. This is especially true 
in the region of the pelvis and the proximal tibia. A defl- 
ciency of soft tissues calls for additional more or less 
plastic reconstructive surgery and although this may solve 
the deficiency, it enlarges the operation and increases the 
risks of complications. 
Large implants, allograft, composites or vascular&d 
autografts for reconstruction do not inevitably lead to an 
increased risk of complications, provided that the amount 
of soft tissues left after resection is sufficient. Under these 
conditions however there is a rule that says: the more ex- 
tensive the reconstruction, the more hazardous the future. 
Complications related to surgery are: haematoma, skin 
necrosis, neurovascular damage, infection, seroma, 
thrombo-embolism, urinary infection, etc. The risk of 
these complications can be reduced by taking the proper 
precautions pre-, peri, and postoperatively. 
5.2. Complications related to implants or grafts 
5.2.1. Implants 
All implants are subject o the response of nature to 
the implantation of a foreign object. In orthopaedic 
surgery this inevitably results in stress shielding, cement 
disease, reaction to polyethylene debris and finally loosen- 
ing [218]. Loosening may be concomitant with infections 
[ 1831. Whether this loosening is related to the technique 
of fixation of the implant is not of special concern to the 
field of limb salvage. Probably the same arguments for 
either type of fixation - cemented or non-cemented - 
are valid, compared to conventional joint replacement. 
However, one of the typical ‘limb salvage factors’ that 
act in favour of long-term fixation to bone is the quality 
of the bone. Most of the patients are young and the good 
quality of their bone may be of benefit to the durability 
of the type of fixation which is used. 
All implants are subject o wear [183,235]. This may 
raise technical problems which may require revision 
surgery. In addition breakage of an implant may also call 
for revision surgery. Many implants consist of an artificial 
joint and a replacing segment. Many complications 
related to wear of the implant obviously occur in the ar- 
tificial joint. In order to make revision surgery easier a 
modular type of prosthesis was developed. This enables 
the surgeon to replace the damaged part without distur- 
bing the fixation of the segmental part to the bone. It 
should be kept in mind that all orthopaedic implants are 
more subject o wear and loosening with complications 
as a consequence, if they are loaded too highly by too 
much activity by the patient. An average level of activity 
without participation of the patient in vigorous sports will 
at least enable a prostheses to survive for 15 years in situ, 
provided that no other risk factors are present. 
5.2.2. Grafts 
5.2.2.1. Autografts. Autografts encompass the most 
biological method of reconstruction. If applied vasculariz- 
ed they heal quite easily and quickly. But even un- 
vascularised they are in this respect superior to 
homogeneous bone. There are two drawbacks. 
Autogenous bone must be harvested elsewhere inthe body 
of the patient and this will almost always result in addi- 
tional scars. 
The second drawback is the risk of fracture, especially 
in the first 6-9 months after the operation, depending on 
the state of vascularisation of the graft. 
Being synonymous with the most biological method of 
reconstruction, and thus enabling the reconstruction to 
act in a natural way, autografts hould be used as much 
as possible. As the availability of autogenous bone is 
limited and most resections in limb saving surgery result 
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in a major defect of the limb involved, most reconstruc- 
tions can at best consist of an autogenous part combined 
with an implant or allograft. 
5.2.2.2. Allografts. This material has an ideal modulus 
of elasticity and perfect ensile and compressive strength. 
Therefore, it is a subject of major interest in limb saving 
surgery [2 191. It is almost impossible to perform allograft 
surgery without a bone bank. Donor selection, antisep- 
sis, harvesting and packing are important features of such 
a bank, the first item is especially of concern with respect 
to HIV. The main problems with allografts are the high 
rate of infection, the risk of fracture [220,221] and the 
risk of delayed union or non-union [ 1861. 
Although Mankin and coworkers [222,223] have pro- 
claimed that an allograft would unite completely and even 
revascularise, many authors nowadays question this state- 
ment, especially since Enneking [224] made the observa- 
tion in retrieval allografts that revitalisation occurred only 
in 20% of the graft. Allografts may act like semibiological 
spacers that are subjected to resorption and im- 
munological processes. Since the complication rate with 
respect o the non-oncologic part of the treatment varies 
between 25 and 45%, it certainly does not represent un- 
complicated surgery. 
5.3. Complications related to chemotherapy 
Especially in cases with pathologic fractures, 
chemotherapy may be responsible for delayed fracture 
healing and may necessitate arly surgical intervention. 
Preoperative chemotherapy may also be associated with 
delayed wound healing and significant blood loss during 
surgery despite normal platelet counts and clotting 
studies. 
During radiotherapy a reduced dose of adriamycine 
and actinomycine D of approximately 30% may be 
necessary inorder to prevent drug-irradiation interactions 
of normal tissues and scar tissue, which could result in 
radiation therapy breaks, severe recall phenomena nd 
severe late effects. 
Most (late) effects of chemotherapy are related to the 
specific drugs used in the various schemes: hearing loss 
due to cisplatin [116], nephrotoxicity due to increasing 
cumulative doses of cisplatin [121], tubular and 
glomerular nephrotoxicity due to increasing cumulative 
doses of ifosfamide [131,225,226], and an increased in- 
cidence of nephrotoxicity after combination of ifosfamide 
and cisplatin [129]. Although the toxicity of high-dose 
methotrexate is generally mild, subclinical (MRI) central 
nervous system toxicity may be present [1171. Moreover, 
there is an increasing awareness of the acute and especially 
late effects of anthracycline therapy given to young peo- 
ple [116,121,126,227]. 
5.4. Complications related to radiation therapy 
Complications of radiation therapy are related to frac- 
tion dose, total dose, irradiated volume, type of tissues 
involved, extent of surgery and chemotherapy given. 
Acute reactions during or shortly after radiation 
therapy are usually limited to erythema, dry or moist des- 
quamation of the skin in the high-dose volume if the 
beams are tangent o the skin, for example in patients with 
proximal thigh tumors. An early complication may be 
delayed wound healing. 
More serious late complications include edema of the 
distal extremity, fibrosis, contracture, atrophy, impaired 
growth, secondary fracture, and radiation induced sar- 
coma. Edema of the distal extremity can be prevented by 
careful sparing of a strip of normal tissue to secure lym- 
phatic drainage, especially in patients with a proximal 
located tumor. The development of fibrosis, contracture 
and atrophy can be decreased by long-term active physical 
therapy. If radiation treatment of the pelvis is required, 
moving the small bowel out of the pelvis should be con- 
sidered, and in young women transposition the ovarium 
should be considered. 
5.5. Psychological complications 
The quality of life in bone tumor patients is affected 
[228] both by limb saving methods as well as by amputa- 
tion. Compared to the purely mechanical aspects of local 
motion, the psychological and social aspects of ad- 
justments are more difIicult to quantify. According to the 
literature [229] self-report questionnaires and semi- 
structured interviews have shown that psychoneurotic and 
somatical distress exists in both groups of patients. In 
terms of physical activity or physical complaints, am- 
putees often do better than limb saving patients. However, 
according to the literature 75% of the amputees report 
difficulties in developing relations with the opposite sex, 
whereas hardly any of the limb salvage patients do [229]. 
Also 75% of the amputees feel embarrassed toshow their 
prostheses and restrict themselves in certain social ac- 
tivities. This does not occur in limb salvage patients. It 
is obvious that future research on the quality of life of 
bone cancer survivors should include prospective valua- 
tion of body image and self-esteem and its impact on 
social skills. 
6. Closing remarks and prospects for the future 
When reviewing the past 20 years, one has to admit that 
the improvements in musculoskeletal oncology are im- 
pressive. Diagnostic imaging has made major steps for- 
ward and local and systemic treatment has also improved, 
due to progress in histopathology, chemotherapy, 
radiotherapy, surgery and bioengineering. World-wide 
scientists, physicians and surgeons are trying to develop 
and use grading systems and instruments to measure the 
outcome of treatment and quality of life. It is obvious that 
these achievements in primary musculoskeletal oncology 
will be of benefit to the treatment of metastatic bone 
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disease in other tumors [230]. Many options are available 
in chemotherapeutic and radiotherapeutic regimens as 
well as methods of reconstruction after resection. To make 
it more complex, combinations of different regimens and 
methods are increasingly used. Limb salvage has ex- 
perienced abig boom in the last decade; progress has been 
made in different methods of treatment, however now the 
time has come to reconsider the achievements. The 
development of more methods of treatment, without a 
reappraisal of what has been achieved, may lead to a fur- 
ther divergence of protocols, without benefit to the goal 
of optimal oncological and functional outcome in limb 
saving surgery. 
All participating disciplines hould come to a consen- 
sus with respect to the instruments that are used for 
measuring; this concerns histopathology, tumor grading, 
outcome of chemotherapy protocols and outcome of 
surgery. The biological behaviour of the tumor has only 
recently been the subject of prospective studies. New 
developments in molecular biology, genetics and DNA 
content are providing important tools in the prediction 
of behaviour, and the outcome of these studies will most 
probably have an impact on treatment strategies [207]. 
Tumor response to adjuvant therapy can be monitored, 
but the efficacy of the present methods hould be improv- 
ed. Positron emission tomography, magnetic resonance 
spectroscopy and gadolinium enhanced MRI might serve 
this purpose. 
In addition orthopaedic surgeons hould aim to pre- 
vent local complications in relation to reconstructions, 
e.g., infection and fractures of allografts and loosening 
of endoprostheses. Further investigations in the im- 
munological status of allografts [207] should be instituted 
as well as studies aimed at understanding the biological 
conduct of endoprosthetic reconstruction. These studies 
call for cooperation with scientists in the fields of im- 
munology and biomechanics. 
In the past major steps forward have been made with 
respect o soft tissue coverage at the time of reconstruc- 
tion. Still we are often faced with deficient soft tissues, 
a situtation needing new techniques which should be 
developed in close cooperation with plastic reconstruc- 
tive surgeons. 
Through a multidisciplinary approach the treating 
physicians and surgeons hould more than in the past set 
up a proper time schedule for each category of patients 
-with adaptation for the individual patient - in order 
to reduce the risk of complications. 
Finally, one has to ascertain whether the variety of 
reconstructions yields functional [207,23 1,232] and 
psychological outcomes that are superior to amputative 
surgery [233]. 
In this respect the position of the rotation plasty 
[64,207,234] is of great interest. A study of this requires 
large groups of patients, the world-wide use of the same 
measuring instruments and close cooperation with 
psychologists and bioengineers. Essentially further pro- 
gress in limb saving surgery can be anticipated by a 
multidisciplinary approach, based on a reappraisal of 
achievements and further developments of new techni- 
ques. However major steps forward in complex areas, for 
instance in tumors of the axial skeleton, call for the ut- 
most ingenuity, which will most probably be the result 
of individual brainwaves. Therefore, limb salvage still is 
an art. 
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